188 related articles for article (PubMed ID: 27213797)
41. [Clinical and immunological comparisons of therapeutic regimens for corneal infiltrates secondary to adenoviral keratoconjunctivitis].
Maychuk DY; Vasil'eva OA; Russu LI; Mezentseva MV
Vestn Oftalmol; 2015; 131(4):49-55. PubMed ID: 26489119
[TBL] [Abstract][Full Text] [Related]
42. Evaluation of tear osmolarity in non-Sjögren and Sjögren syndrome dry eye patients with the TearLab system.
Szalai E; Berta A; Szekanecz Z; Szûcs G; Módis L
Cornea; 2012 Aug; 31(8):867-71. PubMed ID: 22580437
[TBL] [Abstract][Full Text] [Related]
43. Infrared ocular thermography in dogs with and without keratoconjunctivitis sicca.
Biondi F; Dornbusch PT; Sampaio M; Montiani-Ferreira F
Vet Ophthalmol; 2015 Jan; 18(1):28-34. PubMed ID: 23905697
[TBL] [Abstract][Full Text] [Related]
44. A comparison of diagnostic tests for keratoconjunctivitis sicca: lactoplate, Schirmer, and tear osmolarity.
Lucca JA; Nunez JN; Farris RL
CLAO J; 1990; 16(2):109-12. PubMed ID: 2112063
[TBL] [Abstract][Full Text] [Related]
45. Long-term outcome after topical ciclosporin in severe dry eye disease with a 10-year follow-up.
Straub M; Bron AM; Muselier-Mathieu A; Creuzot-Garcher C
Br J Ophthalmol; 2016 Nov; 100(11):1547-1550. PubMed ID: 26823393
[TBL] [Abstract][Full Text] [Related]
46. The cornea in keratoconjunctivitis sicca.
Pflugfelder SC; Stern ME
Exp Eye Res; 2020 Dec; 201():108295. PubMed ID: 33038387
[TBL] [Abstract][Full Text] [Related]
47. Efficacy and Safety of OTX-101, a Novel Nanomicellar Formulation of Cyclosporine A, for the Treatment of Keratoconjunctivitis Sicca: Pooled Analysis of a Phase 2b/3 and Phase 3 Study.
Sheppard J; Kannarr S; Luchs J; Malhotra R; Justice A; Ogundele A; Darby C; Bacharach J
Eye Contact Lens; 2020 Jan; 46 Suppl 1():S14-S19. PubMed ID: 31361655
[TBL] [Abstract][Full Text] [Related]
48. [Impression cytology contribution to differential diagnosis of Sjögren syndrome in the ophthalmological clinic].
Rivas L; Murube J; Shalaby O; Oroza MA; Sanz AI
Arch Soc Esp Oftalmol; 2002 Feb; 77(2):63-72. PubMed ID: 11854857
[TBL] [Abstract][Full Text] [Related]
49. Use of episcleral cyclosporine implants in dogs with keratoconjunctivitis sicca: pilot study.
Barachetti L; Rampazzo A; Mortellaro CM; Scevola S; Gilger BC
Vet Ophthalmol; 2015 May; 18(3):234-41. PubMed ID: 24799029
[TBL] [Abstract][Full Text] [Related]
50. Effect of rebamipide ophthalmic suspension on signs and symptoms of keratoconjunctivitis sicca in Sjögren syndrome patients with or without punctal occlusions.
Arimoto A; Kitagawa K; Mita N; Takahashi Y; Shibuya E; Sasaki H
Cornea; 2014 Aug; 33(8):806-11. PubMed ID: 24977983
[TBL] [Abstract][Full Text] [Related]
51. Contrast sensitivity in patients with keratoconjunctivitis sicca before and after artificial tear application.
Rieger G
Graefes Arch Clin Exp Ophthalmol; 1993 Oct; 231(10):577-9. PubMed ID: 8224932
[TBL] [Abstract][Full Text] [Related]
52. Clinical evaluation of pimecrolimus eye drops for treatment of canine keratoconjunctivitis sicca: a comparison with cyclosporine A.
Ofri R; Lambrou GN; Allgoewer I; Graenitz U; Pena TM; Spiess BM; Latour E
Vet J; 2009 Jan; 179(1):70-7. PubMed ID: 17950639
[TBL] [Abstract][Full Text] [Related]
53. Characterisation of corneal impression cytology in dogs and its application in the diagnosis of keratoconjunctivitis sicca.
Lejarza-Ilaro M; Rodriguez-Alvaro A; Sanchez-Maldonado B; Gonzalez-Alonso-Alegre E
Vet Rec; 2019 Jun; 184(22):678. PubMed ID: 31019006
[TBL] [Abstract][Full Text] [Related]
54. Acupuncture treatment in patients with keratoconjunctivitis sicca: a pilot study.
Grönlund MA; Stenevi U; Lundeberg T
Acta Ophthalmol Scand; 2004 Jun; 82(3 Pt 1):283-90. PubMed ID: 15115449
[TBL] [Abstract][Full Text] [Related]
55. Topical 0.1% prednisolone lowers nerve growth factor expression in keratoconjunctivitis sicca patients.
Lee HK; Ryu IH; Seo KY; Hong S; Kim HC; Kim EK
Ophthalmology; 2006 Feb; 113(2):198-205. PubMed ID: 16360211
[TBL] [Abstract][Full Text] [Related]
56. The Effect of OTX-101 on Tear Production in Patients with Severe Tear-deficient Dry Eye Disease: A Pooled Analysis of Phase 2b/3 and Phase 3 Studies.
Toyos M; Gupta PK; Mitchell B; Karpecki P
Curr Eye Res; 2022 Feb; 47(2):220-224. PubMed ID: 34459350
[TBL] [Abstract][Full Text] [Related]
57. Effect of once daily topical 0.3% naltrexone on tear parameters and corneal sensitivity in dogs with uncontrolled keratoconjunctivitis sicca: a double-masked randomized placebo-controlled clinical trial.
Chen T; Powell CC
Vet Ophthalmol; 2015 Nov; 18(6):497-501. PubMed ID: 25675975
[TBL] [Abstract][Full Text] [Related]
58. Topical administration of cyclosporine for treatment of keratoconjunctivitis sicca in dogs.
Morgan RV; Abrams KL
J Am Vet Med Assoc; 1991 Oct; 199(8):1043-6. PubMed ID: 1748607
[TBL] [Abstract][Full Text] [Related]
59. Advances in the diagnosis and management of keratoconjunctivitis sicca.
Pflugfelder SC
Curr Opin Ophthalmol; 1998 Aug; 9(4):50-3. PubMed ID: 10387469
[TBL] [Abstract][Full Text] [Related]
60. Assessment of tear osmolarity and other dry eye parameters in post-LASIK eyes.
Hassan Z; Szalai E; Berta A; Modis L; Nemeth G
Cornea; 2013 Jul; 32(7):e142-5. PubMed ID: 23665645
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
